Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm
Internal Medicine Journal · 2026
DOI: 10.1111/imj.70368 ↗Kurz gefasst
Fallbericht in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von S Z Xie und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Immunopathology, ICPMR, Westmead Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myocarditis, Algorithms, Myositis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated mortality of up to 50%. Based on international evidence and local experience, we have developed a clinical pathway in our institution as a guide to the early identification and targeted management of this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Immunopathology, ICPMR, Westmead Hospital, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Department of Pharmacology, Sorbonne Université, Inserm, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
- Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
- Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
- Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Zitieren
APA
Xie, S. Z., Salem, J. E., Nagrial, A., Menzies, A., Thomas, L., Ramanathan, S., Berglund, L. J., Sasson, S. C., Grey, A. C., Habib, R., Wong, M., Carlino, M. S., Jeffrey, B., Mo, J., & Lin, M. W. (2026). Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm. Internal Medicine Journal. https://doi.org/10.1111/imj.70368
Vancouver
Xie SZ, Salem JE, Nagrial A, Menzies A, Thomas L, Ramanathan S, et al. Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm. Internal Medicine Journal. 2026. doi:10.1111/imj.70368
BibTeX
@article{Xie2026,
author = {Xie, S Z and Salem, J E and Nagrial, A and Menzies, A and Thomas, L and Ramanathan, S and Berglund, L J and Sasson, S C and Grey, A C and Habib, R and Wong, M and Carlino, M S and Jeffrey, B and Mo, J and Lin, M W},
title = {Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70368}
}
EUVIMED